Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LucidMood is a brand of terpene-enriched cannabis formulations designed to provide predictable, functional effects by combining specific ratios of cannabinoids with botanical terpenes. Most products utilize a 1:1 ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD) to deliver therapeutic benefits while mitigating the intense psychoactivity typically associated with high-THC cannabis. The mechanism of action relies on the modulation of the endocannabinoid system, primarily through the binding of THC to Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2). CBD acts as a non-competitive negative allosteric modulator of CB1 receptors, which helps reduce the anxiety and impairment often induced by THC. Furthermore, the inclusion of specific botanical terpenes—such as limonene, pinene, or myrcene—leverages the "entourage effect" to influence the user's state toward specific outcomes like focus, energy, or relaxation. These products are primarily developed for inhalation via vaporizer pens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LucidMood.